Gossamer Bio Inc GOSS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Presenting on the Emerging Growth Conference 75 Day 2 on September 26
-
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
-
Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now
-
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $0.98
- Day Range
- $0.94–0.99
- 52-Week Range
- $0.45–1.60
- Bid/Ask
- $0.95 / $0.95
- Market Cap
- $215.37 Mil
- Volume/Avg
- 799,423 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 135
- Website
- https://www.gossamerbio.com
Comparables
Valuation
|
Metric
|
GOSS
|
UTHR
|
APLT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 18.22 | — |
Price/Book Value | 2.64 | 2.79 | 13.34 |
Price/Sales | 2.17 | 6.73 | 2,963.35 |
Price/Cash Flow | — | 14.42 | — |
Price/Earnings
GOSS
UTHR
APLT
Financial Strength
|
Metric
|
GOSS
|
UTHR
|
APLT
|
|---|---|---|---|
Quick Ratio | 7.93 | 3.92 | 2.21 |
Current Ratio | 8.21 | 4.35 | 2.30 |
Interest Coverage | −5.27 | 22.67 | — |
Quick Ratio
GOSS
UTHR
APLT
Profitability
|
Metric
|
GOSS
|
UTHR
|
APLT
|
|---|---|---|---|
Return on Assets (Normalized) | −18.30% | 16.95% | −80.98% |
Return on Equity (Normalized) | −126.75% | 20.53% | −319.42% |
Return on Invested Capital (Normalized) | −18.21% | 16.62% | −315.20% |
Return on Assets
GOSS
UTHR
APLT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Srbtdblzqs | Whs | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Mqkdfvpl | Yhsgm | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Phjhkrgxt | Qdzdms | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hvhmflng | Nwyljr | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Txzwlfd | Cqnp | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Xjxgxgln | Hyr | $28.0 Bil | |||
| Moderna Inc
MRNA
| Dyzkblldr | Szgxs | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Nxsfprb | Fxdw | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Djwzdvfgq | Dwwttv | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Xsnyrcbvf | Sfskzv | $12.6 Bil |
United States